Through integrated bioinformatics and clinical validation, we demonstrate that KIF20A overexpression suppresses PD-L1 expression in tumor cells, shapes an immunosuppressive tumor microenvironment, and independently predicts adverse outcomes in immunotherapy-treated patients. Here, KIF20A is linked to neoplasm.